The Role of the Injection Solvent - - Chromatography Online
The Role of the Injection Solvent

LCGC North America
Volume 30, Issue 10, pp. 898-903

Conceptually, What's Going On?

Let's think on a conceptual basis about what is going on with the various examples of Figure 1. If the sample is injected with mobile phase as the injection solvent, it does not have to undergo any chemical changes, so analyte molecules should immediately begin to interact with the stationary phase in the column and undergo normal retention behavior. However, if the injection volume is large enough, you can imagine that some band broadening will take place during the injection. For example, if the injection is extremely large, such as 1 mL, the first sample molecules will travel a significant way through the column before the last of the sample molecules arrive at the inlet. The distance between the first and last sample molecules in a given band determine the peak width, so a broad peak would be observed. At the other extreme, an infinitely small injection would have none of this injection-related broadening, so the peak would be much narrower. As we'll see later, we generally can tolerate an injection volume of approximately 15% of the peak volume of the first peak of interest before we find the injection-related band broadening objectionable.

When the injection solvent is changed, we have another variable in addition to the injection volume mentioned above. In this case, the injected solvent plug must be diluted to the same composition as the mobile phase before "normal" retention can occur. If we think of the injection plug as a ball of solvent at the inlet of the column, it will shrink as it travels through the column, with the outside edges being diluted to the mobile-phase concentration before the center of the ball. While they are inside the ball of the injection solvent, molecules will travel down the column as if that solvent was the mobile phase, whereas those diluted into the mobile phase will now travel at the normal rate in the mobile phase. So if the injection solvent is stronger than the mobile phase, it will tend to sweep analyte molecules through the column more quickly than normal. Because some analyte molecules travel more quickly (in the middle of the injection plug) than others (on the outer edges), injection in a solvent stronger than the mobile phase tends to smear the sample along the column, causing peak distortion. On the other hand, if the injection solvent is weaker than the mobile phase, analyte molecules inside the injection plug will move more slowly than normal, which tends to concentrate them at the column inlet. This often is referred to as on-column concentration and is a technique that can be used to inject large volumes of dilute samples without excessive band broadening. And, as you might expect, the influence of the injection solvent depends on both its volume and how much its composition differs from the mobile phase. A small volume of a strong solvent will be less detrimental than a large volume of the same injection solvent, and at a small enough volume, even a very strong injection solvent will get diluted very quickly, so it will be of little consequence.

How Much Is Too Much?

It can be shown (see discussion of reference 2) that if you want to have <1% loss in resolution because of injection-related peak broadening, the injection volume should be <15% of the peak volume of the first peak of interest if mobile phase is used as the injection solvent. If you are willing to tolerate a 10% loss in resolution, you can increase this to <40% of the peak volume. You can determine the peak volume of a peak by measuring its baseline width (or half-height width 1.7) and multiplying by the flow rate. Alternatively, you can get a good estimate of the peak volume with a few simple calculations that follow. We think it is a good idea to make this calculation and compare the results with the actual measurements as a double-check to make sure there isn't excessive peak broadening because of other causes, such as a bad column.

We can use the data of Figure 1 as an example. The expected width can be estimated from the column plate number, N:

where t R is the retention time and w is the peak width at baseline between tangents drawn to the sides of the peak. Equation 1 can be rearranged to

Now we need a value of N, which for real samples under practical separation conditions can be estimated as

where L is the column length (in millimeters) and d p is the particle diameter (in micrometers). The column of Figure 1 is 250 mm long packed with 10-μm particles, so N ≈ 7500. Injected in the weakest solvent, water (Figure 1d), retention times are 4.72 and 9.05 min. With equation 2, this translates to expected peak widths of 0.218 and 0.418 min, respectively. (The usual disclaimer applies here: Values have been rounded for convenience, so if you try to reproduce these calculations, your results may vary somewhat.) Multiply by the flow rate (1 mL/min) to convert this to peak volumes of 218 and 415 μL.

If we use the <15% rule mentioned at the beginning of this section, maximum recommended injection volumes in mobile phase are then 0.15 218 = 33 μL and 0.15 418 = 63 μL. If we are interested in the first peak, this will be the limiting case, so injection of 5–30 μL in mobile phase would be expected to cause less than 1% loss in resolution. If we are more liberal with the tolerance for loss of resolution, as might be justified in the case of Figure 1, where resolution >>2, the <40% rule should be adequate, or 0.4 218 = 87 μL. Similar calculations can be performed for the data of Table I and we would see that the <15% rule would allow approximately 45-μL injections and the <40% rule would allow approximately 120-μL injections.


blog comments powered by Disqus
LCGC E-mail Newsletters
Global E-newsletters subscribe here:



Column Watch: Ron Majors, established authority on new column technologies, keeps readers up-to-date with new sample preparation trends in all branches of chromatography and reviews developments. LATEST: When Bad Things Happen to Good Food: Applications of HPLC to Detect Food Adulteration

Perspectives in Modern HPLC: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: HPLC for Characterization and Quality Control of Therapeutic Monoclonal Antibodies

MS — The Practical Art: Kate Yu brings her expertise in the field of mass spectrometry and hyphenated techniques to the pages of LCGC. In this column she examines the mass spectrometric side of coupled liquid and gas-phase systems. Troubleshooting-style articles provide readers with invaluable advice for getting the most from their mass spectrometers. LATEST: Radical Mass Spectrometry as a New Frontier for Bioanalysis

LC Troubleshooting: LC Troubleshooting sets about making HPLC methods easier to master. By covering the basics of liquid chromatography separations and instrumentation, John Dolan is able to highlight common problems and provide remedies for them. LATEST: How Much Can I Inject? Part I: Injecting in Mobile Phase

More LCGC Columnists>>

LCGC North America Editorial Advisory Board>>

LCGC Europe Editorial Advisory Board>>

LCGC Editorial Team Contacts>>

Source: LCGC North America,
Click here